cmax-building-south-australia-1

OUR ADVANTAGE

CMAX is Australia’s longest-established, independent facility for the conduct of early-phase clinical trials and is recognised as one of Australia’s most experienced clinical trial service providers.

Discover how CMAX can accelerate your early-phase trial by leveraging the Australian Advantage to deliver rapid start-up timelines, cost-competitive studies, and high-quality, internationally approved data that meets all regulatory requirements.

OUR FACILITY

Our 32+ year history incorporates 23 years at our original site, followed by a decade at our modern, custom-built facility in Adelaide’s BioMed City, opposite the Royal Adelaide Hospital. In 2026, we proudly celebrated 10 years at this facility.

One of the largest health and sciences clusters in the Southern Hemisphere, the BioMed City provides access to state-of-the-art facilities, equipment and world-class medical and pharmacology specialists.

CMAX holds long-established relationships with medical specialists across all of these institutions.

REGULATORY COMPLIANCE

With over 90% of clinical trials conducted for international sponsors, CMAX has extensive experience supporting programs designed to meet global regulatory expectations.

We are US FDA audited and our studies are ICH GCP compliant. Our studies also comply with the registration requirements of the EMA, Japan’s PMDA, NMPA, Health Canada and more.

cmax-global-reach
australian-tax-incentive

Our Services Are Eligible For The Australian R&D Tax Incentive Scheme.

This scheme allows eligible companies to claim up to a 43.5%* rebate on qualifying R&D spend.

*Please note this rebate percentage is subject to change.

  • cmax-research-advantage-2
  • cmax-research-advantage-1a

ETHICS COMPLIANCE

By using the Australian Clinical Trial Notification (CTN) scheme, we can assist you fast-track your clinical trial, reducing the time and cost associated with filing an Investigational New Drug (IND) application - which is not required.

Studies are initiated on local Human Research Ethics Committee (HREC) approval, which occurs typically within six weeks of submission.

JOIN US IN ADVANCING TOMORROW'S HEALTHCARE!